Gyre highlights R&D pipeline progress for degraders and DACs
Gyre says its pipeline of targeted protein degraders and DACs targets unmet needs in oncology, immunology and fibrosis. The company points to China commercial revenues supporting global R&D and cites F351 and ETUARY™ for its fibrosis franchise.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.